wellness · 9 min
KLOW: The Four-Peptide Gut and Inflammation Research Blend
KLOW is a shorthand name used in peptide research circles for a four-component blend targeting gut-barrier integrity and systemic inflammation. It is not a single molecule — it is a stack that delivers four distinct mechanisms in one research protocol.
What KLOW stands for
The letters map (loosely, depending on the source) to the four components:
- K → KPV (Lysine–Proline–Valine, a tripeptide fragment of α-MSH)
- L → Larazotide acetate (zonulin antagonist, tight-junction stabilizer)
- O → an Orexin or LL-37 fragment, depending on the reference protocol (most current KLOW formulations use LL-37, a cathelicidin-derived antimicrobial peptide)
- W → Wharton's Jelly-derived peptides (mesenchymal-tissue signalling factors)
Formulations vary by research group. The version most commonly described in current peptide-research literature uses KPV + Larazotide + LL-37 + Wharton's Jelly.
Why a blend instead of one peptide?
Gut-barrier dysfunction is studied as a multi-mechanism problem. A single peptide can address one pillar but rarely all four:
| Pillar | Mechanism | KLOW component |
|---|---|---|
| Inflammation | Cytokine suppression | KPV |
| Permeability | Tight-junction integrity | Larazotide |
| Microbial pressure | Antimicrobial defense | LL-37 |
| Tissue regeneration | Mesenchymal signalling | Wharton's Jelly |
This is why research protocols combine them — each component closes a different gap.
Component breakdown
KPV
KPV is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH). Published research shows KPV suppressing NF-κB activation and reducing pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in intestinal epithelial cells. It is taken up via the PepT1 transporter, which is over-expressed in inflamed gut tissue — meaning damaged tissue absorbs it preferentially.
Larazotide
Larazotide acetate is a synthetic octapeptide that blocks zonulin signalling. Zonulin is the regulator that opens tight junctions between intestinal epithelial cells. By antagonising zonulin, larazotide tightens the barrier and reduces paracellular permeability. It has been the most studied molecule in celiac-disease barrier research.
LL-37
LL-37 is the only human cathelicidin antimicrobial peptide. It has broad-spectrum activity against bacteria, viruses, and fungi, but its KLOW role is broader than antimicrobial defense — it also modulates immune signalling, supports wound closure, and reduces biofilm formation in the gut lumen.
Wharton's Jelly peptides
Wharton's Jelly is the mucous connective tissue of the umbilical cord. Peptide and exosome fractions derived from it carry signalling factors (TGF-β, IGF-1 fragments, hyaluronic-acid associated peptides) that support mesenchymal regeneration. Research has focused on its role in epithelial recovery and stem-cell signalling.
Common research dose references
Reported research ranges in the literature for the individual components:
- KPV: 250–500 mcg per day subcutaneously, or compounded oral protocols
- Larazotide: 0.25–1 mg per dose, typically 2–3x daily oral in research formulations
- LL-37: 100–300 mcg per day subcutaneously
- Wharton's Jelly peptides: dose varies by extract concentration and is set per research protocol
A KLOW protocol typically runs 4–8 weeks with a 2–4 week wash-out.
Dose figures above are reference figures observed in published peptide and blend research literature. They are not medical advice or recommendations for human use.
Stacking notes
KLOW does not need to stand alone. Research protocols frequently add BPC-157 to extend gut-cytoprotection effects, or KPV alone for shorter inflammation-only investigations.
Use the ZORVYN Dose Calculator for individual component reconstitution math.
Frequently asked questions
Quick answers for research applications. Not medical advice.
What does KLOW stand for?
KLOW is a shorthand name for a four-peptide research blend. The letters map (loosely) to KPV, Larazotide, an LL-37 fragment, and Wharton's Jelly-derived peptides. Component composition varies between research groups, but this is the most commonly described formulation.
Why combine four peptides instead of using one?
Gut-barrier dysfunction is a multi-mechanism research target. KPV addresses inflammation, Larazotide addresses tight-junction permeability, LL-37 addresses microbial pressure, and Wharton's Jelly peptides address tissue regeneration. A single peptide can hit one pillar but not all four — the blend was assembled to cover them simultaneously.
Is KLOW a brand name or a specific formulation?
KLOW is a research shorthand, not a regulated trade name. Different research groups use slightly different component ratios and sometimes substitute Orexin for LL-37. The four-pillar framework is consistent across formulations.
Can KPV be used on its own?
Yes — KPV is a single tripeptide and is studied independently for systemic inflammation and gut research. Using it alone narrows the research question to the inflammation pillar without the additional variables introduced by the other three components.
What is a typical KLOW research cycle length?
Published protocols typically run 4–8 weeks of active dosing followed by a 2–4 week wash-out. This is reference information from research literature, not medical advice.
References
- KPV: A Tripeptide Fragment of α-MSH with Anti-Inflammatory Activity — PubMed (review search)
- Larazotide Acetate as a Tight Junction Regulator in Celiac Disease — PubMed (review search)
- LL-37: The Human Cathelicidin Antimicrobial Peptide — Cellular and Molecular Life Sciences
Mentioned in this article
One-click add to cart, or tap the card to read the full product specs.